By the end of the forecast period in 2017, sales for the bladder cancer market in the 6 Major Markets (6MM) of the US, France, Germany, Italy, Spain and the UK, will increase to $646.6m, representing a CAGR of 31%. The majority of this growth is expected to come from the US, with sales rising considerably, to account for 85.7% of sales in the 6MM by 2017. Overall, growth of the bladder cancer market is forecast to be driven by the entry of three (Telesta Therapeutics’ MCNA and Roche’s atezolizumab in 2016 and Bristol-Myers Squibb’s Opdivoin 2017) pipeline drugs into the market, in addition to a greater number of incident cases of the disease.
GlobalData’s OpportunityAnalyzer: Bladder Cancer – Opportunity Analysis and Forecasts to 2017 report provides analysis of the bladder cancer treatment space across the six major markets of the US, France, Germany, Italy, Spain and the UK, with annualized market data from 2012 and forecast to 2017. It discusses strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the bladder cancer therapeutics market.
Single user price: $9,495